A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-01072013-121936

Type of Document Dissertation
Author Elliott, Natalina Elizabeth
Author's Email Address natalina.e.elliott@gmail.com
URN etd-01072013-121936
Title The role of activating mutations in the FERM domain of janus kinase 3 in the development of adult t-cell leukemia/lymphoma
Degree PhD
Department Cancer Biology
Advisory Committee
Advisor Name Title
Stephen Brandt MD Committee Chair
Scott Hiebert PhD Committee Member
Utpal Davé MD Committee Member
William Pao MD PhD Committee Member
  • adult t-cell leukemia/lymphoma
  • Leukemia
  • FERM
  • JAK3
  • ATLL
  • HTLV-1
  • IL-2
  • mutation
  • t-cell
Date of Defense 2012-11-12
Availability unrestricted
Adult T-cell leukemia/lymphoma (ATLL) is an incurable peripheral T-cell malignancy where most patients succumb within the first year of diagnosis. Development of ATLL requires human T-cell lymphotrophic virus type 1 (HTLV-I) retroviral infection followed by accumulation of somatic mutations and changes in gene expression. The discovery of genes and pathways involved in the initiation of ATLL may provide novel therapeutic targets for treatment of this fatal disease. Since the IL-2 signaling pathway plays an important role in ATLL development, mutational analysis of IL-2 signaling pathway components should yield a better understanding of disease progression and outcome. Janus kinase 3 (JAK3), a nonreceptor tyrosine kinase is a key kinase upstream in the IL-2 signaling pathway. Activating somatic mutations in JAK3 have been described in leukemias and lymphomas including acute megakaryoblastic leukemia and natural killer/T-cell lymphoma. Three mutations in the regulatory FERM domain of JAK3 were identified in four of the thirty-six ATLL patients screened and no mutations were found in the twenty-four screened ethnically matched controls. These somatic, missense mutations occurred in the amino terminal regulatory FERM domain. JAK3 FERM domain may play an autoregulatory role by inhibiting kinase activity in the absence of IL-2. In cell culture assays all three FERM domain mutations induce gain of function in JAK3 and can be inhibited with a JAK specific kinase inhibitor, tofacitinib. One of the JAK3 FERM domain mutations (E183G) was characterized in vivo and found to be oncogenic in cooperation with the loss of cell cycle regulatory proteins p16(INK4a) and p14(ARF). These findings emphasize the importance of JAK3 activation in ATLL development and offer a novel therapeutic target for this incurable disease.
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  ELLIOTTNEthesis042713.pdf 5.56 Mb 00:25:43 00:13:13 00:11:34 00:05:47 00:00:29

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.